Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The socioeconomic burden of pediatric tuberculosis and role of child-sensitive social protection.
Shah K, Nakafeero J, Kadota JL, Wambi P, Nanyonga G, Kiconco E, Deus A, Sekadde MP, Nabukenya-Mudiope MG, Tukamuhebwa HA, Mupere E, Mohanty S, Cattamanchi A, Wobudeya E, Shete PB, Jaganath D. Shah K, et al. Among authors: kadota jl. BMC Public Health. 2023 Nov 25;23(1):2339. doi: 10.1186/s12889-023-17084-7. BMC Public Health. 2023. PMID: 38007477 Free PMC article.
Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in Uganda.
Kadota JL, Musinguzi A, Nabunje J, Welishe F, Ssemata JL, Bishop O, Berger CA, Patel D, Sammann A, Katahoire A, Nahid P, Belknap R, Phillips PPJ, Namusobya J, Kamya M, Handley MA, Kiwanuka N, Katamba A, Dowdy D, Semitala FC, Cattamanchi A. Kadota JL, et al. Implement Sci. 2020 Aug 12;15(1):65. doi: 10.1186/s13012-020-01025-8. Implement Sci. 2020. PMID: 32787925 Free PMC article.
Acceptance and completion of rifapentine-based TB preventive therapy (3HP) among people living with HIV (PLHIV) in Kampala, Uganda-patient and health worker perspectives.
Semitala FC, Musinguzi A, Ssemata J, Welishe F, Nabunje J, Kadota JL, Berger CA, Katamba A, Kiwanuka N, Kamya MR, Dowdy D, Cattamanchi A, Katahoire AR. Semitala FC, et al. Among authors: kadota jl. Implement Sci Commun. 2021 Jun 30;2(1):71. doi: 10.1186/s43058-021-00173-2. Implement Sci Commun. 2021. PMID: 34193311 Free PMC article.
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Semitala FC, Kadota JL, Musinguzi A, Nabunje J, Welishe F, Nakitende A, Akello L, Bishop O, Patel D, Sammann A, Nahid P, Belknap R, Kamya MR, Handley MA, Phillips PPJ, Katahoire A, Berger CA, Kiwanuka N, Katamba A, Dowdy DW, Cattamanchi A. Semitala FC, et al. Among authors: kadota jl. PLoS Med. 2021 Dec 16;18(12):e1003875. doi: 10.1371/journal.pmed.1003875. eCollection 2021 Dec. PLoS Med. 2021. PMID: 34914696 Free PMC article. Clinical Trial.
Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda.
Sung J, Musinguzi A, Kadota JL, Baik Y, Nabunje J, Welishe F, Bishop O, Berger CA, Katahoire A, Nakitende A, Nakimuli J, Akello L, Kasidi JR, Kunihira Tinka L, Kamya MR, Sohn H, Kiwanuka N, Katamba A, Cattamanchi A, Dowdy DW, Semitala FC. Sung J, et al. Among authors: kadota jl. Int J Tuberc Lung Dis. 2023 Jun 1;27(6):458-464. doi: 10.5588/ijtld.22.0679. Int J Tuberc Lung Dis. 2023. PMID: 37231600 Free PMC article.
29 results